延岡市の福祉施設における言語聴覚障害児・者の実態について

A survey was conducted to understand the nature and management of persons with speech-language-hearing (SLH) and related disorders in facilities of child welfare and the elderly in Nobeoka city. The questionnaire was sent to 84 facilities and approximately a half of the facilities (51.2%) responded. No speech therapist (ST) was employed in these facilities. SLH disorders were identified in the 16.9% of individuals who resided in and commuted to these facilities. Overall, language disorders, i.c., language delay and aphasia, were the most frequently identified SLH disorder, followed by dysphagia and hearing disorders in the facilities for the elderly and articulation disorders in the child welfare facilities. The post-onset period of SLH and related disorders was seldom known. SLH therapy was taken only for 3.4% individuals. Paraprofessionals had involved for the management of SLH and related disorders. It is assumed that no formal evaluation was conducted in these facilities. Some paraprofessionals had joined a study group (16% of the facilities). It is hoped to establish the system of the evaluation and management of SLH and related disorders in these facilities in Nobeoka city

Discovery of Novel 5‑(Piperazine-1-carbonyl)pyridin-2(1<i>H</i>)‑one Derivatives as Orally eIF4A3-Selective Inhibitors

Starting from our previous eIF4A3-selective inhibitor <b>1a</b>, a novel series of (piperazine-1-carbonyl)­pyridin-2­(1<i>H</i>)-one derivatives was designed, synthesized, and evaluated for identification of orally bioavailable probe molecules. Compounds <b>1o</b> and <b>1q</b> showed improved physicochemical and ADMET profiles, while maintaining potent and subtype-selective eIF4A3 inhibitory potency. In accord with their promising PK profiles and results from initial in vivo PD studies, compounds <b>1o</b> and <b>1q</b> showed antitumor efficacy with T/C values of 54% and 29%, respectively, without severe body weight loss. Thus, our novel series of compounds represents promising probe molecules for the in vivo pharmacological study of selective eIF4A3 inhibition